Hemoglobin and Children’s cancers - Brief Report, DOI: 10.13140/RG.2.2.21321.52325, ISSN 2753-8176 (online)

Hemoglobin and Children’s cancers - Brief Report, DOI:10.13140/RG.2.2.21321.52325, ISSN 2753-8176 (online) Ana Pedro (1) 1. Gwyntwr1386 Pharmacy, Regus Chester Business Park, Heronsway,Chester CH4 9QR, United Kingdom info@gwyntwr1386.com Wilms tumor or nephroblastoma, is a cancer of the kidneys which occurs most commonly as a renal tumor in child patients (1). Neuroblastoma, a rare type of cancer, also mostly affects babies and young children. It develops from neuroblasts which were left behind during baby's development in the womb (2).Most often starts from one of the adrenal glands but can also develop in the neck, chest, abdomen or spine (3). IMR5 is a neuroblastoma cell line, derived from a male, aged 1 year and 1 month, derived from a metastatic site in the abdomen (4). SKNBe2 is another neuroblastoma cell line, derived from a 2 year old male and from bone marrow metastasis after chemotherapy and radiotherapy (5). Finally, CCG9911 is a Wilm’s tumor cell line (6). Here we analyze by proteomic analysis, the precipitates derived from conditioned media of IMR5, SKNBe2a and CCG9911 cell lines. All these cells lines express HBA (P69905) and HBB (P68871). Only neuroblastoma cell lines express HBE (P02100). HBG2 (E9PBW4) is expressed in SKNBe2a and CCG9911 cell lines. Finally, prohibitin (P35232) is only found in the CCG9911 cell line (table 1). Materials and Methods Proteomic analysis was performed at the Rockefeller University, Proteomics Center as described in Hamidi et al., 2017 (7). Only proteins with Mascot scores of approximately 90 or >90 were considered (8) The proteomic analysis excel files and each correspondent sample details were generously and kindly shared and donated by Dr. David Lyden, Weill Cornell Medical College, New York, USA. Original data files can be found at Hemoglobin and osteoblasts markers in bone cancer | Zenodo References 1. van den Heuvel-Eibrink, Marry M.; Hol, Janna A.; Pritchard-Jones, Kathy; van Tinteren, Harm; Furtwängler, Rhoikos; Verschuur, Arnauld C.; Vujanic, Gordan M.; Leuschner, Ivo; Brok, Jesper; Rübe, Christian; Smets, Anne M.; Janssens, Geert O.; Godzinski, Jan; Ramírez-Villar, Gema L.; de Camargo, Beatriz (2017-12-01). "Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol". Nature Reviews Urology. 14 (12): 743–752. doi:10.1038/nrurol.2017.163. ISSN 1759-4820. S2CID 9418050. 2. https://www.nhs.uk/conditions/neuroblastoma/ 3. National Cancer Institute. 20 January 2016. Archived from the original on 10 November 2016. Retrieved 9 November 2016. 4. Cellosaurus cell line IMR-5 (CVCL_1306) 5. SK-N-BE(2) - CRL-2271 | ATCC 6. Ortiz et al. 2019. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumor. JCI Insight. 2019;4(15):e127098. 7. https://www.biorxiv.org/content/10.1101/202291v1 8.

https://f1000research.com/articles/7-283